Literature DB >> 15026338

Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Shmuel Yaccoby1, Michele J Wezeman, Aminah Henderson, Michele Cottler-Fox, Qing Yi, Bart Barlogie, Joshua Epstein.   

Abstract

We have investigated the interaction between tumor cells and specific cells in their microenvironment using myeloma as a model. The role of myeloma-induced osteoclastogenesis in the disease was studied ex vivo. Myeloma plasma cells freshly purified from patients' bone marrow attracted committed osteoclast (OC) precursors (n = 9; P < 0.01) and in 22 experiments directly induced their differentiation to multinucleated, bone-resorbing OCs (P < 0.00002) in a receptor activator of nuclear factor-kappaB ligand-mediated mechanism that was inhibited by the receptor activator of nuclear factor-kappaB (RANK-Fc) in 13 experiments by 71 +/- 12% (P < 0.008). In contrast, myeloma cells did not induce differentiation of peripheral blood mononuclear cells. Myeloma plasma cells cocultured with OCs retained their viability and proliferative activity for >13 weeks. After 14 days in coculture, the plasma cells from 29 patients had higher viability (P < 2 x 10(-6)), fewer apoptotic cells (P < 4 x 10(-15)), and a higher bromodeoxyuridine labeling index (P < 0.0006) than controls. Physical contact between OCs and myeloma cells was required for these effects to take place. No differences were observed between OCs from healthy donors and those from myeloma patients. Blocking interleukin 6 activity, while reducing survival of myeloma cells, had no effect on their proliferative activity. These results support data obtained from animal models and clinical observations on the essential role of the microenvironment in tumor sustenance and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026338     DOI: 10.1158/0008-5472.can-03-1131

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

1.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 2.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

3.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 4.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 5.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

6.  The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Authors:  Simona Colla; Fenghuang Zhan; Wei Xiong; Xiaosong Wu; Hongwei Xu; Owen Stephens; Shmuel Yaccoby; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

7.  A murine model of myeloma that allows genetic manipulation of the host microenvironment.

Authors:  Jessica A Fowler; Gregory R Mundy; Seint T Lwin; Conor C Lynch; Claire M Edwards
Journal:  Dis Model Mech       Date:  2009-09-24       Impact factor: 5.758

8.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

9.  Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.

Authors:  Ya-Wei Qiang; Yu Chen; Nathan Brown; Bo Hu; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Br J Haematol       Date:  2009-11-24       Impact factor: 6.998

10.  Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Sharmin Khan; Shmuel Yaccoby
Journal:  Cancer Lett       Date:  2009-05-15       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.